The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1

Kali Janes, Joshua W. Little, Chao Li, Leesa Bryant, Collin Chen, Zhoumou Chen, Krzysztof Kamocki, Timothy Doyle, Ashley Snider, Emanuela Esposito, Salvatore Cuzzocrea, Erhard Bieberich, Lina Obeid, Irina Petrache, Grant Nicol, William L. Neumann, Daniela Salvemini

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The ceramide-sphingosine 1-phosphate (S1P) rheostat is important in regulating cell fate. Several chemotherapeutic agents, including paclitaxel (Taxol), involve pro-apoptotic ceramide in their anticancer effects. The ceramide-to-S1P pathway is also implicated in the development of pain, raising the intriguing possibility that these sphingolipids may contribute to chemotherapyinduced painful peripheral neuropathy, which can be a critical dose-limiting side effect of many widely used chemotherapeutic agents.Wedemonstrate that the development of paclitaxel-induced neuropathic pain was associated with ceramide and S1P formation in the spinal dorsal horn that corresponded with the engagement of S1P receptor subtype 1 (S1PR 1)-dependent neuroinflammatory processes as follows: activation of redox-sensitive transcription factors (NFκB) and MAPKs (ERK and p38) as well as enhanced formation of pro-inflammatory and neuroexcitatory cytokines (TNF-α and IL-1β). Intrathecal delivery of the S1PR1 antagonist W146 reduced these neuroinflammatory processes but increased IL-10 and IL-4, potent anti-inflammatory/neuroprotective cytokines. Additionally, spinal W146 reversed established neuropathic pain. Noteworthy, systemic administration of the S1PR1 modulator FTY720 (Food and Drug Administrationapproved for multiple sclerosis) attenuated the activation of these neuroinflammatory processes and abrogated neuropathic pain without altering anticancer properties of paclitaxel and with beneficial effects extended to oxaliplatin. Similar effects were observed with other structurally and chemically unrelated S1PR1 modulators (ponesimod and CYM-5442) and S1PR1 antagonists (NIBR-14/15) but not S1PR1 agonists (SEW2871). Our findings identify for the first time the S1P/S1PR1 axis as a promising molecular and therapeutic target in chemotherapy-induced painful peripheral neuropathy, establish a mechanistic insight into the biomolecular signaling pathways, and provide the rationale for the clinical evaluation of FTY720 in chronic pain patients.

Original languageEnglish (US)
Pages (from-to)21082-21097
Number of pages16
JournalJournal of Biological Chemistry
Volume289
Issue number30
DOIs
StatePublished - Jul 25 2014

Fingerprint

Lysosphingolipid Receptors
Ceramides
Neuralgia
Paclitaxel
Chemical activation
Maintenance
oxaliplatin
Peripheral Nervous System Diseases
Modulators
Cytokines
Sphingolipids
Chemotherapy
p38 Mitogen-Activated Protein Kinases
Interleukin-1
Chronic Pain
Interleukin-4
Interleukin-10
Multiple Sclerosis
Oxidation-Reduction
Anti-Inflammatory Agents

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. / Janes, Kali; Little, Joshua W.; Li, Chao; Bryant, Leesa; Chen, Collin; Chen, Zhoumou; Kamocki, Krzysztof; Doyle, Timothy; Snider, Ashley; Esposito, Emanuela; Cuzzocrea, Salvatore; Bieberich, Erhard; Obeid, Lina; Petrache, Irina; Nicol, Grant; Neumann, William L.; Salvemini, Daniela.

In: Journal of Biological Chemistry, Vol. 289, No. 30, 25.07.2014, p. 21082-21097.

Research output: Contribution to journalArticle

Janes, K, Little, JW, Li, C, Bryant, L, Chen, C, Chen, Z, Kamocki, K, Doyle, T, Snider, A, Esposito, E, Cuzzocrea, S, Bieberich, E, Obeid, L, Petrache, I, Nicol, G, Neumann, WL & Salvemini, D 2014, 'The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1', Journal of Biological Chemistry, vol. 289, no. 30, pp. 21082-21097. https://doi.org/10.1074/jbc.M114.569574
Janes, Kali ; Little, Joshua W. ; Li, Chao ; Bryant, Leesa ; Chen, Collin ; Chen, Zhoumou ; Kamocki, Krzysztof ; Doyle, Timothy ; Snider, Ashley ; Esposito, Emanuela ; Cuzzocrea, Salvatore ; Bieberich, Erhard ; Obeid, Lina ; Petrache, Irina ; Nicol, Grant ; Neumann, William L. ; Salvemini, Daniela. / The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. In: Journal of Biological Chemistry. 2014 ; Vol. 289, No. 30. pp. 21082-21097.
@article{d995fe1e4d734a2cb9823388995e3bcb,
title = "The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1",
abstract = "The ceramide-sphingosine 1-phosphate (S1P) rheostat is important in regulating cell fate. Several chemotherapeutic agents, including paclitaxel (Taxol), involve pro-apoptotic ceramide in their anticancer effects. The ceramide-to-S1P pathway is also implicated in the development of pain, raising the intriguing possibility that these sphingolipids may contribute to chemotherapyinduced painful peripheral neuropathy, which can be a critical dose-limiting side effect of many widely used chemotherapeutic agents.Wedemonstrate that the development of paclitaxel-induced neuropathic pain was associated with ceramide and S1P formation in the spinal dorsal horn that corresponded with the engagement of S1P receptor subtype 1 (S1PR 1)-dependent neuroinflammatory processes as follows: activation of redox-sensitive transcription factors (NFκB) and MAPKs (ERK and p38) as well as enhanced formation of pro-inflammatory and neuroexcitatory cytokines (TNF-α and IL-1β). Intrathecal delivery of the S1PR1 antagonist W146 reduced these neuroinflammatory processes but increased IL-10 and IL-4, potent anti-inflammatory/neuroprotective cytokines. Additionally, spinal W146 reversed established neuropathic pain. Noteworthy, systemic administration of the S1PR1 modulator FTY720 (Food and Drug Administrationapproved for multiple sclerosis) attenuated the activation of these neuroinflammatory processes and abrogated neuropathic pain without altering anticancer properties of paclitaxel and with beneficial effects extended to oxaliplatin. Similar effects were observed with other structurally and chemically unrelated S1PR1 modulators (ponesimod and CYM-5442) and S1PR1 antagonists (NIBR-14/15) but not S1PR1 agonists (SEW2871). Our findings identify for the first time the S1P/S1PR1 axis as a promising molecular and therapeutic target in chemotherapy-induced painful peripheral neuropathy, establish a mechanistic insight into the biomolecular signaling pathways, and provide the rationale for the clinical evaluation of FTY720 in chronic pain patients.",
author = "Kali Janes and Little, {Joshua W.} and Chao Li and Leesa Bryant and Collin Chen and Zhoumou Chen and Krzysztof Kamocki and Timothy Doyle and Ashley Snider and Emanuela Esposito and Salvatore Cuzzocrea and Erhard Bieberich and Lina Obeid and Irina Petrache and Grant Nicol and Neumann, {William L.} and Daniela Salvemini",
year = "2014",
month = "7",
day = "25",
doi = "10.1074/jbc.M114.569574",
language = "English (US)",
volume = "289",
pages = "21082--21097",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "30",

}

TY - JOUR

T1 - The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1

AU - Janes, Kali

AU - Little, Joshua W.

AU - Li, Chao

AU - Bryant, Leesa

AU - Chen, Collin

AU - Chen, Zhoumou

AU - Kamocki, Krzysztof

AU - Doyle, Timothy

AU - Snider, Ashley

AU - Esposito, Emanuela

AU - Cuzzocrea, Salvatore

AU - Bieberich, Erhard

AU - Obeid, Lina

AU - Petrache, Irina

AU - Nicol, Grant

AU - Neumann, William L.

AU - Salvemini, Daniela

PY - 2014/7/25

Y1 - 2014/7/25

N2 - The ceramide-sphingosine 1-phosphate (S1P) rheostat is important in regulating cell fate. Several chemotherapeutic agents, including paclitaxel (Taxol), involve pro-apoptotic ceramide in their anticancer effects. The ceramide-to-S1P pathway is also implicated in the development of pain, raising the intriguing possibility that these sphingolipids may contribute to chemotherapyinduced painful peripheral neuropathy, which can be a critical dose-limiting side effect of many widely used chemotherapeutic agents.Wedemonstrate that the development of paclitaxel-induced neuropathic pain was associated with ceramide and S1P formation in the spinal dorsal horn that corresponded with the engagement of S1P receptor subtype 1 (S1PR 1)-dependent neuroinflammatory processes as follows: activation of redox-sensitive transcription factors (NFκB) and MAPKs (ERK and p38) as well as enhanced formation of pro-inflammatory and neuroexcitatory cytokines (TNF-α and IL-1β). Intrathecal delivery of the S1PR1 antagonist W146 reduced these neuroinflammatory processes but increased IL-10 and IL-4, potent anti-inflammatory/neuroprotective cytokines. Additionally, spinal W146 reversed established neuropathic pain. Noteworthy, systemic administration of the S1PR1 modulator FTY720 (Food and Drug Administrationapproved for multiple sclerosis) attenuated the activation of these neuroinflammatory processes and abrogated neuropathic pain without altering anticancer properties of paclitaxel and with beneficial effects extended to oxaliplatin. Similar effects were observed with other structurally and chemically unrelated S1PR1 modulators (ponesimod and CYM-5442) and S1PR1 antagonists (NIBR-14/15) but not S1PR1 agonists (SEW2871). Our findings identify for the first time the S1P/S1PR1 axis as a promising molecular and therapeutic target in chemotherapy-induced painful peripheral neuropathy, establish a mechanistic insight into the biomolecular signaling pathways, and provide the rationale for the clinical evaluation of FTY720 in chronic pain patients.

AB - The ceramide-sphingosine 1-phosphate (S1P) rheostat is important in regulating cell fate. Several chemotherapeutic agents, including paclitaxel (Taxol), involve pro-apoptotic ceramide in their anticancer effects. The ceramide-to-S1P pathway is also implicated in the development of pain, raising the intriguing possibility that these sphingolipids may contribute to chemotherapyinduced painful peripheral neuropathy, which can be a critical dose-limiting side effect of many widely used chemotherapeutic agents.Wedemonstrate that the development of paclitaxel-induced neuropathic pain was associated with ceramide and S1P formation in the spinal dorsal horn that corresponded with the engagement of S1P receptor subtype 1 (S1PR 1)-dependent neuroinflammatory processes as follows: activation of redox-sensitive transcription factors (NFκB) and MAPKs (ERK and p38) as well as enhanced formation of pro-inflammatory and neuroexcitatory cytokines (TNF-α and IL-1β). Intrathecal delivery of the S1PR1 antagonist W146 reduced these neuroinflammatory processes but increased IL-10 and IL-4, potent anti-inflammatory/neuroprotective cytokines. Additionally, spinal W146 reversed established neuropathic pain. Noteworthy, systemic administration of the S1PR1 modulator FTY720 (Food and Drug Administrationapproved for multiple sclerosis) attenuated the activation of these neuroinflammatory processes and abrogated neuropathic pain without altering anticancer properties of paclitaxel and with beneficial effects extended to oxaliplatin. Similar effects were observed with other structurally and chemically unrelated S1PR1 modulators (ponesimod and CYM-5442) and S1PR1 antagonists (NIBR-14/15) but not S1PR1 agonists (SEW2871). Our findings identify for the first time the S1P/S1PR1 axis as a promising molecular and therapeutic target in chemotherapy-induced painful peripheral neuropathy, establish a mechanistic insight into the biomolecular signaling pathways, and provide the rationale for the clinical evaluation of FTY720 in chronic pain patients.

UR - http://www.scopus.com/inward/record.url?scp=84905369183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905369183&partnerID=8YFLogxK

U2 - 10.1074/jbc.M114.569574

DO - 10.1074/jbc.M114.569574

M3 - Article

C2 - 24876379

AN - SCOPUS:84905369183

VL - 289

SP - 21082

EP - 21097

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 30

ER -